Evidence map›Paper›PMID 33579808›Full record

ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2021

Landscape Analysis of Phase 2 and 3 Clinical Trials for Targeted Radionuclide Therapy.

Erik Mittra, Lisa Bodei

Abstract read
In one paragraph

Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. European journal of hospital pharmacy : science and practice · 2024
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Erik MittraDivision of Nuclear Medicine and Molecular Imaging, Oregon Health & Science University, Portland, Oregon; and mittra@ohsu.edu.
Lisa BodeiMolecular Imaging and Therapy Service, Memorial Sloan Kettering Cancer Center, New York, New York.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Clinical Trials, Phase II as TopicClinical Trials, Phase III as TopicHumansMolecular Targeted TherapyNeoplasmsRadioisotopesRadiopharmaceuticalsRadioisotopesRadiopharmaceuticalsradioisotope therapyradioligand therapyradiopharmaceutical therapy

Identifiers

PMID33579808
PMCPMC9364763

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.